Table of Contents  
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 169  

Author reply

Department of Pharmacology, Government Medical College and Hospital, Sector 32 B, Chandigarh, India

Date of Submission08-Feb-2014
Date of Decision24-Feb-2014
Date of Acceptance24-Feb-2014
Date of Web Publication7-Apr-2014

Correspondence Address:
Sangeeta Bhanwra
House No. 1152, Sector 32 B, Chandigarh 160 030
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

How to cite this article:
Bhanwra S, Ahluwalia K. Author reply. J Pharmacol Pharmacother 2014;5:169

How to cite this URL:
Bhanwra S, Ahluwalia K. Author reply. J Pharmacol Pharmacother [serial online] 2014 [cited 2022 Jan 24];5:169. Available from:


The European Heart Rhythm Association guidelines on the new orally available anticoagulants in patients of atrial fibrillation as mentioned in the letter definitely provide a more rational and a practical approach to the use of these agents. Guidelines have highlighted the concern for various existing and possible drug interactions for apixaban, rivaroxaban and dabigatran. The outcome of interactions of various drugs with apixaban is still awaited but nevertheless, the guidelines have emphasized caution for usage of such drugs with apixaban.

As far as the use of these drugs in the patients with deranged renal functions is concerned, it was considered unsafe, but the guidelines have provided us with the definite value of creatinine clearance beyond which none of these drugs can be used.

The information provided in the letter is useful and will enable the readers toward judicious use of new oral anticoagulants.


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded198    
    Comments [Add]    

Recommend this journal